Research ExplorerPublicationsSurvival of patients with synchronous and metachronous color...

Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?

Standard

Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? / Bockhorn, Maximilian; Frilling, Andreja; Frühauf, Nils R; Neuhaus, Jan; Molmenti, Ernesto; Trarbach, Tanja; Malagó, Massimo; Lang, Hauke; Broelsch, Christoph E.

In: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, Vol. 12, No. 8, 01.08.2008, p. 1399-405.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bockhorn, M, Frilling, A, Frühauf, NR, Neuhaus, J, Molmenti, E, Trarbach, T, Malagó, M, Lang, H & Broelsch, CE 2008, 'Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?', Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, vol. 12, no. 8, pp. 1399-405. https://doi.org/10.1007/s11605-008-0508-9

APA

Bockhorn, M., Frilling, A., Frühauf, N. R., Neuhaus, J., Molmenti, E., Trarbach, T., Malagó, M., Lang, H., & Broelsch, C. E. (2008). Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 12(8), 1399-405. https://doi.org/10.1007/s11605-008-0508-9

Vancouver

Bockhorn M, Frilling A, Frühauf NR, Neuhaus J, Molmenti E, Trarbach T et al. Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2008 Aug 1;12(8):1399-405. https://doi.org/10.1007/s11605-008-0508-9

Bibtex

@article{6e9bdb5ec6bc45d6bfe696f91bba887d,
title = "Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?",
abstract = "BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants.STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters. A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison.RESULTS: Twenty-three patients in group A received only an explorative laparotomy. Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44). Thirty-day mortality was 3%. Morbidity was observed in 10% of the patients. One-, 3-, and 5-year overall survival rates for synchronous metastases were 86%, 68%, and 47%, respectively. The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05). Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28). There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05). Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only.CONCLUSIONS: Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases. The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.",
keywords = "Adult, Aged, Aged, 80 and over, Colorectal Neoplasms, Disease-Free Survival, Female, Follow-Up Studies, Germany, Hepatectomy, Humans, Laparotomy, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate",
author = "Maximilian Bockhorn and Andreja Frilling and Fr{\"u}hauf, {Nils R} and Jan Neuhaus and Ernesto Molmenti and Tanja Trarbach and Massimo Malag{\'o} and Hauke Lang and Broelsch, {Christoph E}",
year = "2008",
month = aug,
day = "1",
doi = "10.1007/s11605-008-0508-9",
language = "English",
volume = "12",
pages = "1399--405",
journal = "J GASTROINTEST SURG",
issn = "1091-255X",
publisher = "Springer New York",
number = "8",

}

RIS

TY - JOUR

T1 - Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?

AU - Bockhorn, Maximilian

AU - Frilling, Andreja

AU - Frühauf, Nils R

AU - Neuhaus, Jan

AU - Molmenti, Ernesto

AU - Trarbach, Tanja

AU - Malagó, Massimo

AU - Lang, Hauke

AU - Broelsch, Christoph E

PY - 2008/8/1

Y1 - 2008/8/1

N2 - BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants.STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters. A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison.RESULTS: Twenty-three patients in group A received only an explorative laparotomy. Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44). Thirty-day mortality was 3%. Morbidity was observed in 10% of the patients. One-, 3-, and 5-year overall survival rates for synchronous metastases were 86%, 68%, and 47%, respectively. The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05). Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28). There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05). Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only.CONCLUSIONS: Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases. The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.

AB - BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants.STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters. A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison.RESULTS: Twenty-three patients in group A received only an explorative laparotomy. Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44). Thirty-day mortality was 3%. Morbidity was observed in 10% of the patients. One-, 3-, and 5-year overall survival rates for synchronous metastases were 86%, 68%, and 47%, respectively. The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05). Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28). There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05). Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only.CONCLUSIONS: Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases. The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Colorectal Neoplasms

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Germany

KW - Hepatectomy

KW - Humans

KW - Laparotomy

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Survival Rate

U2 - 10.1007/s11605-008-0508-9

DO - 10.1007/s11605-008-0508-9

M3 - SCORING: Journal article

C2 - 18521698

VL - 12

SP - 1399

EP - 1405

JO - J GASTROINTEST SURG

JF - J GASTROINTEST SURG

SN - 1091-255X

IS - 8

ER -